Company Filing History:
Years Active: 2019-2020
Title: Dieter Söll: Innovator in Selenocysteine Polypeptides
Introduction
Dieter Söll is a prominent inventor based in Guilford, CT (US). He has made significant contributions to the field of biochemistry, particularly in the development of methods for producing selenocysteine-containing polypeptides. His innovative work has led to the filing of multiple patents that enhance the understanding and application of non-standard amino acids in protein engineering.
Latest Patents
Dieter Söll holds 2 patents that focus on groundbreaking methodologies. His latest patents include compositions and methods for making selenocysteine-containing polypeptides. These patents disclose non-naturally occurring tRNA and methods for using them in the recombinant expression of proteins engineered to include one or more selenocysteine residues. The non-naturally occurring tRNA can be utilized for the recombinant manufacture of selenocysteine-containing polypeptides encoded by mRNA without the need for an SECIS element. Additionally, his work provides compositions and methods for preparing polypeptides with multiple iterations of non-standard amino acids, allowing for greater yields than conventional methods.
Career Highlights
Dieter Söll is affiliated with Yale University, where he continues to advance research in biochemistry and molecular biology. His innovative approaches have positioned him as a leader in the field, contributing to the understanding of protein synthesis and the incorporation of non-standard amino acids.
Collaborations
Dieter has collaborated with notable colleagues, including Farren J. Isaacs and Miriam Amiram. These partnerships have further enriched his research and expanded the impact of his inventions in the scientific community.
Conclusion
Dieter Söll's contributions to the field of biochemistry through his patents and research at Yale University highlight his role as an influential inventor. His work on selenocysteine-containing polypeptides and non-standard amino acids continues to pave the way for advancements in protein engineering.